Literature DB >> 8688322

A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice.

J Kurebayashi1, M Kurosumi, H Sonoo.   

Abstract

Parathyroid hormone-related protein (PTHrP) is the main cause of humoral hypercalcaemia of malignancy (HHM). We recently established a new human breast cancer cell line, designated KPL-3C, from the malignant effusion of a breast cancer patient with HHM. Morphological, cytogenetic and immunohistochemical analyses indicated that the cell line is derived from human breast cancer. The KPL-3C cells stably secrete immunoreactive PTHrP measured by a two-site immunoradiometric assay, possess both oestrogen and progesterone receptors and are tumorigenic in female nude mice. The addition of phorbol-12-myristate-13-acetate to the medium significantly increased PTHrP secretion from the cells. In contrast, hydrocortisone, medroxyprogesterone acetate and 22-oxacalcitriol decreased PTHrP secretion in a dose-dependent manner. Unexpectedly, a number of microcalcifications were observed in the transplanted tumours. Radiographical examination indicated that the microcalcifications in the tumours are very similar to those commonly observed in human breast cancer. These findings suggest that this KPL-3C cell line may be useful for studying the regulatory mechanisms of PTHrP secretion and the mechanisms that lead to the deposition of microcalcifications in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8688322      PMCID: PMC2074563          DOI: 10.1038/bjc.1996.338

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

1.  Parathyroid Hormone-related Protein in Breast Cancer Tissues: Relationship between Primary and Metastatic Sites.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

2.  Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.

Authors:  J J Body; A Borkowski; A Cleeren; O L Bijvoet
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

3.  Separation of parathyroid hormone-like activity from transforming growth factor-alpha and -beta in the canine adenocarcinoma (CAC-8) model of humoral hypercalcemia of malignancy.

Authors:  J I Merryman; T J Rosol; C L Brooks; C C Capen
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

4.  Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors.

Authors:  G J Strewler; R D Williams; R A Nissenson
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

5.  Production of interleukin 1 alpha-like factor and colony-stimulating factor by a squamous cell carcinoma of the thyroid (T3M-5) derived from a patient with hypercalcemia and leukocytosis.

Authors:  K Sato; Y Fujii; M Ono; H Nomura; K Shizume
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

6.  Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression.

Authors:  J Henderson; M Sebag; J Rhim; D Goltzman; R Kremer
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

7.  The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases.

Authors:  N Kohno; S Kitazawa; M Fukase; Y Sakoda; Y Kanbara; Y Furuya; O Ohashi; Y Ishikawa; Y Saitoh
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  Production of parathyroid hormone-related protein in tumour xenografts in nude mice presenting with hypercalcaemia.

Authors:  Y Miyake; K Yamaguchi; S Honda; K Nagasaki; T Tsuchihashi; M Mori; S Kimura; K Abe
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

9.  Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines.

Authors:  M A Birch; J A Carron; M Scott; W D Fraser; J A Gallagher
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.

Authors:  J Walls; W A Ratcliffe; A Howell; N J Bundred
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more
  12 in total

1.  Clinical Significance of Microcalcifications Detection in Invasive Breast Carcinoma.

Authors:  Yuki Hashimoto; Aya Murata; Naoki Miyamoto; Toshihiro Takamori; Yuta Hosoda; Yukari Endo; Yuka Kodani; Kengo Sato; Keiko Hosoya; Kiyosuke Ishiguro; Yasuaki Hirooka
Journal:  Yonago Acta Med       Date:  2015-08-18       Impact factor: 1.641

2.  Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.

Authors:  Junichi Kurebayashi; Naoki Kanomata; Takuya Moriya; Yuji Kozuka; Mika Watanabe; Hiroshi Sonoo
Journal:  BMC Cancer       Date:  2010-10-20       Impact factor: 4.430

3.  Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by antioestrogens in KPL-3C human breast cancer cells.

Authors:  J Kurebayashi; H Sonoo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.

Authors:  Tetsuro Yoshimaru; Masato Komatsu; Yasuo Miyoshi; Junko Honda; Mitsunori Sasa; Toyomasa Katagiri
Journal:  Cancer Sci       Date:  2015-04-01       Impact factor: 6.716

5.  BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.

Authors:  Nam-Hee Kim; Tetsuro Yoshimaru; Yi-An Chen; Taisuke Matsuo; Masato Komatsu; Yasuo Miyoshi; Eiji Tanaka; Mitsunori Sasa; Kenji Mizuguchi; Toyomasa Katagiri
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

6.  A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells.

Authors:  Tetsuro Yoshimaru; Masaya Ono; Yoshimi Bando; Yi-An Chen; Kenji Mizuguchi; Hiroshi Shima; Masato Komatsu; Issei Imoto; Keisuke Izumi; Junko Honda; Yasuo Miyoshi; Mitsunori Sasa; Toyomasa Katagiri
Journal:  Nat Commun       Date:  2017-05-30       Impact factor: 14.919

7.  Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells.

Authors:  Junichi Kurebayashi; Yoshikazu Koike; Yusuke Ohta; Wataru Saitoh; Tetsumasa Yamashita; Naoki Kanomata; Takuya Moriya
Journal:  Cancer Sci       Date:  2017-04-27       Impact factor: 6.716

8.  Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity.

Authors:  Gongping Shi; Yoko Yoshida; Kanako Yuki; Tomomi Nishimura; Yukiko Kawata; Masahiro Kawashima; Keiko Iwaisako; Kiyotsugu Yoshikawa; Junichi Kurebayashi; Masakazu Toi; Makoto Noda
Journal:  Oncotarget       Date:  2016-12-13

9.  Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.

Authors:  S Okubo; J Kurebayashi; T Otsuki; Y Yamamoto; K Tanaka; H Sonoo
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

10.  Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.

Authors:  Tetsuro Yoshimaru; Masato Komatsu; Etsu Tashiro; Masaya Imoto; Hiroyuki Osada; Yasuo Miyoshi; Junko Honda; Mitsunori Sasa; Toyomasa Katagiri
Journal:  Sci Rep       Date:  2014-12-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.